An Exploratory Pilot Study with Plasma Protein Signatures Associated with Response of Patients with Depression to Antidepressant Treatment for 10 Weeks
Major depressive disorder (MDD) is a leading cause of global disability with a chronic and recurrent course. Recognition of biological markers that could predict and monitor response to drug treatment could personalize clinical decision-making, minimize unnecessary drug exposure, and achieve better...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-10-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/8/11/455 |
| _version_ | 1797549620355661824 |
|---|---|
| author | Eun Young Kim Hee-Sung Ahn Min Young Lee Jiyoung Yu Jeonghun Yeom Hwangkyo Jeong Hophil Min Hyun Jeong Lee Kyunggon Kim Yong Min Ahn |
| author_facet | Eun Young Kim Hee-Sung Ahn Min Young Lee Jiyoung Yu Jeonghun Yeom Hwangkyo Jeong Hophil Min Hyun Jeong Lee Kyunggon Kim Yong Min Ahn |
| author_sort | Eun Young Kim |
| collection | DOAJ |
| description | Major depressive disorder (MDD) is a leading cause of global disability with a chronic and recurrent course. Recognition of biological markers that could predict and monitor response to drug treatment could personalize clinical decision-making, minimize unnecessary drug exposure, and achieve better outcomes. Four longitudinal plasma samples were collected from each of ten patients with MDD treated with antidepressants for 10 weeks. Plasma proteins were analyzed qualitatively and quantitatively with a nanoflow LC−MS/MS technique. Of 1153 proteins identified in the 40 longitudinal plasma samples, 37 proteins were significantly associated with response/time and clustered into six according to time and response by the linear mixed model. Among them, three early-drug response markers (PHOX2B, SH3BGRL3, and YWHAE) detectable within one week were verified by liquid chromatography-multiple reaction monitoring/mass spectrometry (LC-MRM/MS) in the well-controlled 24 patients. In addition, 11 proteins correlated significantly with two or more psychiatric measurement indices. This pilot study might be useful in finding protein marker candidates that can monitor response to antidepressant treatment during follow-up visits within 10 weeks after the baseline visit. |
| first_indexed | 2024-03-10T15:18:10Z |
| format | Article |
| id | doaj.art-c2c5af49059e40729fa4d877040cdfcc |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-10T15:18:10Z |
| publishDate | 2020-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-c2c5af49059e40729fa4d877040cdfcc2023-11-20T18:47:53ZengMDPI AGBiomedicines2227-90592020-10-0181145510.3390/biomedicines8110455An Exploratory Pilot Study with Plasma Protein Signatures Associated with Response of Patients with Depression to Antidepressant Treatment for 10 WeeksEun Young Kim0Hee-Sung Ahn1Min Young Lee2Jiyoung Yu3Jeonghun Yeom4Hwangkyo Jeong5Hophil Min6Hyun Jeong Lee7Kyunggon Kim8Yong Min Ahn9Mental Health Center, Seoul National University Health Care Center, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, KoreaAsan Institute for Life Sciences, Asan Medical Center, Seoul 05505, KoreaInstitute for Systems Biology, Seattle, Washington, DC 98109, USAAsan Institute for Life Sciences, Asan Medical Center, Seoul 05505, KoreaConvergence Medicine Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul 05505, KoreaDepartment of Biomedical Sciences, University of Ulsan College of Medicine, Seoul 05505, KoreaDoping Control Center, Korea Institute of Science and Technology, Hwarang-ro 14-gil 5, Seongbuk-gu, Seoul 02792, KoreaDepartment of Psychiatry & Behavioral Science, National Cancer Center, Ilsandong-gu, Goyang-si, Gyeonggi-do 10408, KoreaAsan Institute for Life Sciences, Asan Medical Center, Seoul 05505, KoreaDepartment of Neuropsychiatry, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, KoreaMajor depressive disorder (MDD) is a leading cause of global disability with a chronic and recurrent course. Recognition of biological markers that could predict and monitor response to drug treatment could personalize clinical decision-making, minimize unnecessary drug exposure, and achieve better outcomes. Four longitudinal plasma samples were collected from each of ten patients with MDD treated with antidepressants for 10 weeks. Plasma proteins were analyzed qualitatively and quantitatively with a nanoflow LC−MS/MS technique. Of 1153 proteins identified in the 40 longitudinal plasma samples, 37 proteins were significantly associated with response/time and clustered into six according to time and response by the linear mixed model. Among them, three early-drug response markers (PHOX2B, SH3BGRL3, and YWHAE) detectable within one week were verified by liquid chromatography-multiple reaction monitoring/mass spectrometry (LC-MRM/MS) in the well-controlled 24 patients. In addition, 11 proteins correlated significantly with two or more psychiatric measurement indices. This pilot study might be useful in finding protein marker candidates that can monitor response to antidepressant treatment during follow-up visits within 10 weeks after the baseline visit.https://www.mdpi.com/2227-9059/8/11/455major depressive disorderlongitudinal studyLC-MS/MSplasma protein biomarkerdrug response monitoringmultiple reaction monitoring |
| spellingShingle | Eun Young Kim Hee-Sung Ahn Min Young Lee Jiyoung Yu Jeonghun Yeom Hwangkyo Jeong Hophil Min Hyun Jeong Lee Kyunggon Kim Yong Min Ahn An Exploratory Pilot Study with Plasma Protein Signatures Associated with Response of Patients with Depression to Antidepressant Treatment for 10 Weeks Biomedicines major depressive disorder longitudinal study LC-MS/MS plasma protein biomarker drug response monitoring multiple reaction monitoring |
| title | An Exploratory Pilot Study with Plasma Protein Signatures Associated with Response of Patients with Depression to Antidepressant Treatment for 10 Weeks |
| title_full | An Exploratory Pilot Study with Plasma Protein Signatures Associated with Response of Patients with Depression to Antidepressant Treatment for 10 Weeks |
| title_fullStr | An Exploratory Pilot Study with Plasma Protein Signatures Associated with Response of Patients with Depression to Antidepressant Treatment for 10 Weeks |
| title_full_unstemmed | An Exploratory Pilot Study with Plasma Protein Signatures Associated with Response of Patients with Depression to Antidepressant Treatment for 10 Weeks |
| title_short | An Exploratory Pilot Study with Plasma Protein Signatures Associated with Response of Patients with Depression to Antidepressant Treatment for 10 Weeks |
| title_sort | exploratory pilot study with plasma protein signatures associated with response of patients with depression to antidepressant treatment for 10 weeks |
| topic | major depressive disorder longitudinal study LC-MS/MS plasma protein biomarker drug response monitoring multiple reaction monitoring |
| url | https://www.mdpi.com/2227-9059/8/11/455 |
| work_keys_str_mv | AT eunyoungkim anexploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT heesungahn anexploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT minyounglee anexploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT jiyoungyu anexploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT jeonghunyeom anexploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT hwangkyojeong anexploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT hophilmin anexploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT hyunjeonglee anexploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT kyunggonkim anexploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT yongminahn anexploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT eunyoungkim exploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT heesungahn exploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT minyounglee exploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT jiyoungyu exploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT jeonghunyeom exploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT hwangkyojeong exploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT hophilmin exploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT hyunjeonglee exploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT kyunggonkim exploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks AT yongminahn exploratorypilotstudywithplasmaproteinsignaturesassociatedwithresponseofpatientswithdepressiontoantidepressanttreatmentfor10weeks |